Wednesday, February 27, 2008 New Green Baron Stock Alert Axial Vector Engine Corporation (PK: AXVC, Frankfurt: BAE1) Members Should Add AXVC to Watch List and Listen to Call Today – Stock up over 11% yesterday Investor Conference Call Scheduled Today, February 27th at 4:15 EST U.S - Call 1(800)704-9804 Enter Participant Code 986729# International Access Call – 1(404)920-6604 Please let this alert act as our final reminder to listen to the investor conference call scheduled today at 4:15 EST for Axial Vector. Once again, The Green Baron Report believes Axial Vector Engine Corp. (AXVC) is about to shock the world when the company’s finished production unit will be on hand at the WETEX 2008 (Water, Energy Technology and Environment Exhibition in Dubai March 11-13 – www.wetex.ae/.) Based on our research, we believe AXVC will validate its technology developments in the month of March and the stock will react very positively. As we stated yesterday, AXVC stock traded primarily between $1 per share and $5 per share throughout 2005 and 2006. Unfortunately, it took longer for the Company to deliver its finished products to market, and the stock sagged over the past year. Just recently, the Company has found serious support from one of its largest shareholders, Emirates International Capital Advisory, a Dubai based advisory firm chaired by His Royal Highness Sheikh Marwan bin Mohammed bin Rashid Al Maktoum. EICA continuously seeks out niche markets that have been overlooked and targets best in class solutions and groundbreaking technologies to bring to market. See two recent press releases below: Axial Vector Announces Ahmed Khalifa as New Chairman of the Board of Directors DUBAI, United Arab Emirates, Feb. 20 /PRNewswire-FirstCall/ -- Axial Vector Engine Corporation (Pink Sheets: AXVC; Frankfurt Symbol: BAE1) today announced the appointment of Mr. Ahmed Khalifa as Chairman of the Board of Directors. On February 27th, 2008 at 4:15 pm Eastern Standard Time Mr. Khalifa will host an investor conference call to update the investment community on the global launch of its ultra efficient GENSETs and other important breakthroughs. Completed 200kw GENSET is confirmed for air shipment on March 3, 2008 to Dubai. Ahmed Khalifa stated, "With the launch of our first products now imminent and our pending project finance agreement with Emirates Capital we can now fully execute our business plan of bringing lower cost electricity, engines and many other important products to the worlds markets." Mr. Khalifa further stated "our global conference call will include members of our staff and senior officials of Emirates International Capital Advisory (www.emiratescapital.net) who will preview our unique financing system to allow rapid deployment of our products to be produced and sold in large quantities". Conference Participant:
1. At the specified time, dial the Access Number 1.800.704.9804.
2. When prompted, enter your Participant Code followed by #.
3. Your Participant Code is 986729#.
For International Access Call 1 404 920 6604
News Announced February 14 About WETEX 2008 Conference March 11-13Shipping of Production Unit Sent to Dubai, United Arab Emirates for Premier Low Cost MULTI FUEL GENSET Production Units to be Introduced at Dubai WETEX 2008 Conference March 11-13 in DubaiDUBAI, United Arab Emirates, Feb. 14 /PRNewswire-FirstCall/ -- Axial Vector Engine Corporation (Pink Sheets: AXVC) (Frankfurt: BAE1), today announced that the company's finished production unit will be on hand at the WETEX 2008 (Water, Energy Technology and Environment Exhibition in Dubai March 11-13 2008). http://www.wetex.ae/. Ahmed Khalifa, acting CEO, stated, "On Demand Portable Power is now affordable with our ultra efficient, multi fuel, 200 KW units. These GENSETS are the only ones with the ability to 'join' up to five units, creating one megawatt of portable low cost power, which is deliverable anywhere using the first true multi-fuel system. A fraction of the weight of competitors and very low cost of the energy produced will go a long way to alleviating power shortages in many parts of the world. Coupled with the fact that we shall be using a competitive pricing structure for our GENSETS, we believe that our products will be received favorably in the marketplace." All systems will have additional outside performance verifications done in order to penetrate the power market and provide peace of mind to our customers. Dealer and distributor negotiations have commenced with much interest from the world's 'power players'. Axial Vector(TM) Engine Corporation is a publicly traded company (Pink Sheets: AXVC) that owns, develops and licenses proprietary intellectual property regarding unique internal combustion engine technologies. AVEC is applying these technologies to develop an exciting, new, smaller and lighter internal combustion engine that produces significantly greater horsepower and three times more torque on less fuel than conventional engines of similar size. Forward-Looking Statements This press release may be deemed to contain forward-looking information. Any forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements, including statements as to industry trends, future economic performance, anticipated profitability, anticipated revenues and expenses, and products or service line growth, may be significantly and materially impacted by certain risks and uncertainties, including, but not limited to, failure to meet operating objectives or to execute the operating plan, completion, and other economic factors. Additional risks and uncertainties are described in the Company's public filings with the Securities and Exchange Commission. SOURCE Axial Vector Engine Corporation Axial Vector Engine Corporation 1-503-471-1348
Focus Pick Update Immunosyn Corporation (BB: IMYN) IMYN Rallies on News Released Yesterday Immunosyn Releases Wound Healing Photographs from the First Phase ‘Proof of Concept Trial’ in Europe for Treatment of Diabetic Ulcers with Biopharmaceutical SF-1019 January Focus Pick Rallies over 23% in one day to close at $2.85 per share up .55 per share on the day The Green Baron Report remains confident that our January Focus Pick Immunosyn Corporation (BB: IMYN) will eventually break out. Biotech stock investments are generally difficult to time because there can be a long lag between new developments. However, research suggests that Immunosyn’s SF-1019 has the potential to affect a number of clinical conditions, and good news can surface on any numbers of studies that are ongoing. Watch for IMYN to continue its climb as more investors become aware of the SF-1019’s potential. LA JOLLA, Calif., Feb. 26 /PRNewswire-FirstCall/ -- Immunosyn Corporation (OTC Bulletin Board: IMYN) received permission from Argyll Biotechnologies, LLC to release before and after wound healing photographs resulting from subcutaneous injections of the biopharmaceutical SF-1019 from the first phase of a formal "Proof of Concept Trial" which has been successfully completed in Europe for treatment of Diabetic Ulcers with SF-1019. (Photo: http://www.newscom.com/cgi-bin/prnh/20080226/LATU104) The primary purpose of the "Proof of Concept Trial" is to further evaluate the safety and efficacy of SF-1019 in the treatment of Diabetic Ulceration and its effect on Diabetic Polyneuropathy in Type 1 Diabetes Mellitus by both subcutaneous injection and by topical application. The first phase, which is now complete, involved an extremely small cohort of patients. "Seldom is it possible to demonstrate the efficacy of a biopharmaceutical such as SF-1019 in a media that people can actually see," said Stephen D. Ferrone, President and CEO of Immunosyn. "Photographic evidence such as this is indeed significant." The images seen below as well as additional images are also available for viewing at http://www.immunosyn.com/du-beforeandafter.html. A specialized grid referenced Polaroid camera was used for photographic documentation in order to prevent digital manipulation and to substantiate authenticity of the images. "This first very important phase in the development of SF-1019, which was undertaken at a European venue by Argyll Biotechnologies, has indicated that SF-1019 promotes wound healing and almost certainly induces growth factors. When systemically delivered (subcutaneously), SF-1019 has shown the resolution of long standing chronic lesions which is very impressive," stated Professor Angus Dalgleish, MBBS, BSc, MD, FRCP, RACP, FRCPath, FMedSci, Chief Scientist and Consultant Medical Officer for Argyll Biotechnologies, LLC. Professor Dalgleish is also a member of Immunosyn's Scientific Advisory Board. "Because of the positive results, which both the independent clinical team and I have observed during the first phase of the 'Proof of Concept Trial' and with the absence of any adverse side effects, the trial will go forward to the next phase and will be expanded to cover a wider group of patients," advised Clinical Director for Argyll Biotechnologies, David Maizels, MD, MSc, MRCS, LRCP. It is expected that the next phase will be completed during the first half of 2008 and if successful larger-scale independently-managed formal Clinical Trials, leading to a licensed product in Europe, will take place shortly thereafter at a world-renowned specialist wound healing clinic. According to the International Diabetes Federation (IDF), globally, an approximated 246 million people have Diabetes Mellitus, of which one in six will develop a diabetic foot ulcer. Also according to IDF, extensive epidemiological surveys indicate that between 40% and 70% of all lower extremity amputations are related to diabetes and that every 30 seconds a leg is lost to diabetes somewhere in the world. Argyll Biotechnologies, LLC is Immunosyn's strategic partner and largest shareholder, as well as the developer and licensor of SF-1019 for which Immunosyn has been granted the world-wide rights to market, sell and distribute under an exclusive license agreement. About Immunosyn Corporation La Jolla, CA-headquartered Immunosyn Corporation (IMYN.OTC.BB) plans to market and distribute life enhancing therapeutics. Currently, the company has exclusive worldwide rights from its largest shareholder, Argyll Biotechnologies, LLC, to market, sell and distribute SF-1019, a compound that was developed from extensive research into Biological Response Modifiers (BRMs). Argyll Biotechnologies, LLC has initiated the process for regulatory approval of SF-1019 in several countries and preparations for clinical trials are underway in both the US and Europe. Research suggests that SF-1019 has the potential to affect a number of clinical conditions including complications from Diabetic Mellitus such as Diabetic Neuropathy (DN) and diabetic ulcers (DU), auto-immune disorders such as Multiple Sclerosis (MS) and neurological disorders such as Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Reflex Sympathetic Dystrophy Syndrome (RSD or RSDS). (For more information on Immunosyn and SF-1019 go to http://www.immunosyn.com) The above news release contains forward-looking statements. These statements are based on assumptions that management believes are reasonable based on currently available information, and include statements regarding the intent, belief or current expectations of the Company and its management. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance, and are subject to a wide range of business risks, external factors and uncertainties. Actual results may differ materially from those indicated by such forward-looking statements. For additional information, please consult the Company's most recent public filings and Annual Report on Form 10-K for its most recent fiscal year. The Company assumes no obligation to update the information contained in this press release, whether as a result of new information, future events or otherwise. CONTACT: Bill Kraus/Lisa Baker/Devon Blaine
The Blaine Group
310/360-1499
310/360-1498 (FAX)
blaine@blainegroupinc.com
SOURCE Immunosyn Corporation
|
